Clinical trial / 2015
High-dose intravenous vitamin C was generally well tolerated alongside chemotherapy.
A phase I-II trial examined high-dose intravenous vitamin C added to chemotherapy in 14 patients with advanced cancer and limited treatment response expectations. The infusions were generally well tolerated, with only transient adverse events recorded. Pharmacokinetic analyses indicated higher tissue uptake of vitamin C following chemotherapy without increases in urinary oxalic acid. Three patients exhibited brief periods of stable disease and functional improvement.
- Study type
- Phase I-II clinical trial
- Who was studied
- 14 patients with advanced cancer
- What was measured
- Safety, pharmacokinetics, and clinical response
THE PAPER
High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial.
Hoffer LJ, Robitaille L, Zakarian R, Melnychuk D, Kavan P, Agulnik J, Cohen V, Small D, Miller WH. PLoS One, 2015.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.